Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL study of intravenous GLP-1 versus insulin for stress-induced hyperglycaemia in critical illness
ACTRN12622001409763Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Glucagon-like peptide 1 and human insulin (2 arms), sponsored by Royal Adelaide Hospital. Primary endpoint: Total time outside target glucose range. Started Feb 2023; status: recruiting.
02
Drugs
Glucagon-like peptide 1human insulin
Beyond the preview
Go deeper on ACTRN12622001409763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001409763.